BAY-1163877
BAY-1163877 Basic information
- Product Name:
- BAY-1163877
- Synonyms:
-
- BAY-1163877
- Rogaratinib
- 4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f]-[1,2,4]triazin-7-yl]methyl}piperazin-2-one
- Rogaratinib (BAY1163877)
- 2-Piperazinone, 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methylbenzo[b]thien-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]-
- Rogaratinib,inhibit,BAY 1163877,Fibroblast growth factor receptor,BAY-1163877,FGFR,Inhibitor
- CAS:
- 1443530-05-9
- MF:
- C23H26N6O3S
- MW:
- 466.56
- Mol File:
- 1443530-05-9.mol
More
Less
BAY-1163877 Chemical Properties
- Density
- 1.48±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:5.0(Max Conc. mg/mL);10.72(Max Conc. mM)
- form
- Solid
- pka
- 15.49±0.20(Predicted)
- color
- White to light yellow
More
Less
BAY-1163877 Usage And Synthesis
Uses
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively[1][2].
IC 50
FGFR1; FGFR2; FGFR3; FGFR4
References
[1] Heroult M, et al. Preclinical profile of BAY 1163877-a selective pan-FGFR inhibitor in phase 1 clinical trial[J]. Cancer Res, 2014, 74(suppl 19): 1739a.
[2] Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241. DOI:10.1038/oncsis.2016.48
BAY-1163877Supplier
Shanghai Topbiochem Technology Co., Ltd
- Tel
- 021-58170097
- info@topbiochem.com
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
Shanghaizehan biopharma technology co., Ltd.
- Tel
- 021-61350663 13052117465
- sales@zehanbiopharma.com
Shanghai Biolang biotechnology Co.,Ltd
- Tel
- 17764003753
- 2326587775@qq.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com